Ozge A Alper

US Patent:

20060063214, Mar 23, 2006

Filed:

Sep 17, 2004

Appl. No.:

10/943793

Inventors:

Ozge Alper - Bethesda MD, US

International Classification:

G01N 33/574

US Classification:

435007230

Abstract:

Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods.

US Patent:

20100272640, Oct 28, 2010

Filed:

Jan 7, 2010

Appl. No.:

12/684090

Inventors:

Ozge ALPER - Bethesda MD, US

International Classification:

A61K 51/10
C07K 16/18
C07H 21/04
A61K 49/00
A61P 35/00
C12N 15/63
C12N 5/00
C12P 21/06
G01N 33/574

US Classification:

424 149, 5303891, 536 2353, 424 91, 5303913, 4353201, 435325, 435 696, 435 723

Abstract:

The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.

US Patent:

20110136148, Jun 9, 2011

Filed:

Nov 11, 2010

Appl. No.:

12/944510

Inventors:

Ozge ALPER - Bethesda MD, US

Assignee:

ALPER BIOTECH LLC - Rockville MD

International Classification:

G01N 33/53
C07K 16/22
C12N 15/13
C12N 15/63
C12N 1/00
C12N 5/00

US Classification:

435 723, 5303892, 5303879, 5303911, 5303913, 5303917, 536 2353, 4353201, 435243, 435325, 436501

Abstract:

The disclosure relates to monoclonal antibodies (mAbs) preferentially selective for soluble GMF-B (sGMF-B) antigens or for sGMF-B as well as other forms of GMF-B, hybridoma lines that secrete these antibodies or fragments thereof, and the use of such antibodies and antibody fragments to preferentially detect sGMF-B antigens, including for example those expressed by cancer cells or in patients with cancer or dementia. Other aspects of the present disclosure relate to antibodies that are specific to or demonstrate preferential binding to a soluble or secreted form of GMF-B. Yet other aspects relate to antibodies or antibody fragments that are capable of reducing the activity of GMF-B in at least one form, including a soluble form or a secreted form. The present disclosure further relates to monoclonal, chimeric antibodies and fragments thereof, processes for producing such antibodies and their fragments, and their therapeutic and diagnostic uses, including in the treatment and detection of cancer, e.g., human breast, ovary, head, neck, and brain, and dementia. Methods and kits for the immunodetection and immunotherapy of cells or samples which express sGMF-B antigens, e.g., from patient and non-patient samples, are also disclosed.

US Patent:

20120301395, Nov 29, 2012

Filed:

Aug 7, 2012

Appl. No.:

13/568969

Inventors:

Ozge ALPER - Bethesda MD, US

Assignee:

ALPER BIOTECH, LLC - Rockville MD

International Classification:

C07K 16/18
A61K 51/10
C12N 15/13
C12N 15/63
C12N 5/10
G01N 33/566
G01N 33/574
G01N 21/64
C12N 1/21
C12N 1/19
C07K 17/00
C12P 21/02

US Classification:

424 149, 5303898, 5303911, 5303913, 5303917, 536 2353, 4353201, 435 696, 435 71, 5303879, 43525231, 435 792, 43525233, 4352523, 43525234, 43525421, 43525423, 435332

Abstract:

The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.

US Patent:

20140322224, Oct 30, 2014

Filed:

Nov 9, 2012

Appl. No.:

14/357120

Inventors:

- Rockville MD, US
Ozge Alper - Bethesda MD, US

Assignee:

ALPER BIOTECH LLC - Rockville MD

International Classification:

C07K 16/18
G01N 33/574
A61K 49/00

US Classification:

4241391, 5303879, 5303913, 5303917, 536 2353, 4353201, 435331, 435 71, 4352523, 43525233, 43525231, 43525234, 4352542, 43525421, 43525423

Abstract:

The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage prostate cancer are encompassed.